HOME | LOG IN | SIGN UP

Validation of VitBOD, a simple burden of disease instrument for vitiligo

Vaneeta Sheth, Sujeeta Silwal

Abstract


Background: Vitiligo is a chronic, progressive condition of skin depigmentation that has a negative impact on quality of life. 

Aim of the study:  To validate a novel, low-burden tool to more accurately assess the burden of disease on those affected. 

Methods: The VitBOD was designed as a ten question tool using visual analog scales to assess various physical, mental and emotional domains of health specific to vitiligo.  90 subjects with dermatologist-confirmed vitiligo agreed to complete the self-administered VitBOD questionnaire along with the previously validated Short Form-36 (SF-36). 

Results: 67 fully completed questionnaires were returned.  VitBOD scores were transformed to fit the direction of the SF-36 for statistical analysis.  Median overall scores were significantly lower for VitBOD as shown by the paired t-test (75.3 vs 85, p=0.015).  VitBOD showed high internal consistency (Cronbach’s alpha = 0.9).  Vitality, social, and mental health domains correlated positively with SF-36. 

Conclusion: VitBOD can reliably measure burden of disease in vitiligo as well as the SF-36 with distinct advantages being ease and speed of use along with disease-specificity.  Testing in broader patient populations would be useful for further validation. 


Keywords


vitiligo; quality of life; burden of disease; mental health

Full Text:

References


REFERENCES

Bhandarkar, SS, Kundu, RV. Quality-of-life issues in vitiligo. Dermatol Clin, 2012; 2: 255-68.

Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015; Jan 14.

Shankar, DS, Shashikala, K, Madala, R. Clinical patterns of vitiligo and its associated co morbidities: A prospective controlled cross-sectional study in South India. Indian Dermatol Online J 2012; 3(2): 114-8.

Wang, KY, Wang, KH, Zhang, ZP. Health- related quality of life and marital quality of vitiligo patients in China. J Eur Acad Dermatol Venereol 2011; 25(4): 429-35.

Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gend Med 2006; 3(2): 124-30.

Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5(2):105-10.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 3:210-6.

Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997; 37(1):41-50.

Lilly, E, Lu, PD, Borovicka, JH, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 2013; 69(1):e11-8.

Krishna GS, Ramam M, Mehta M, et al. Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo. Indian J Dermatol Venereol Leprol 2013; 79(2):205-10.

Gupta V, Sreenivas V, Mehta M, et al. Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol 2014; 171(5):1084-90.

Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305(6846):160-4.

Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41(3):151-8.

Tabolli S1, Mozzetta A, Antinone V, et al. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire. Br J Dermatol 2008; 158(5):1029-34.

Ahmed A, Leon A, Butler DC, Reichenberg J. Quality of side effects of common dermatological diseases. Semin Cutan Med Surg. 2013; 32(2):101-9.




DOI: http://dx.doi.org/10.18103/mra.v0i3.123

Refbacks

  • There are currently no refbacks.